Document Detail

Leflunomide in monotherapy of rheumatoid arthritis: meta‑analysis of randomized trials.
MedLine Citation:
PMID:  22353705     Owner:  NLM     Status:  In-Data-Review    
INTRODUCTION: Rheumatoid arthritis (RA) is a chronic systemic disease of the connective tissue that leads to progressive joint destruction, disability, withdrawal from occupational activity, and premature death.
OBJECTIVES: The aim of the paper was to evaluate the efficacy and safety of leflunomide compared with placebo, methotrexate, and sulfasalazine in monotherapy of RA.
PATIENTS AND METHODS: A systematic search of databases (MEDLINE, EMBASE, Cochrane CENTRAL) was performed. Only randomized blind trials were included into the analysis. The quality of the trials was assessed by the Jadad scale. A quantitative synthesis of the results was performed (meta‑analysis).
RESULTS: The analysis included 7 trials involving 2861 patients (1432 on leflunomide, 312 on placebo, 922 on methotrexate, and 133 on sulfasalazine). Leflunomide, compared with placebo, increased the probability of the American College of Rheumatology 20% improvement (ACR20) response 2‑fold (relative risk [RR], 2.02; 95% CI, 1.46-2.80) and the probability of ACR50 response 4‑fold (RR, 4.36; 95% CI, 2.33-8.17), after 1 year of treatment. Efficacy of leflunomide did not differ from that of methotrexate with reference to the majority of endpoints. Leflunomide showed partial superiority over methotrexate in the percentage of patients obtaining ACR50 and ACR70 response, doctor’s assessment of the disease activity, reduction in C‑reactive protein (CRP) levels, and improvement of the quality of life (assessed with the modified health assessment questionnaire [HAQ]). Sulfasalazine showed partial superiority in the reduction of erythrocyte sedimentation rate, while leflunomide was superior to sulfasalazine the ACR20 and ACR50 clinical response, quality of life (assessed with the HAQ), doctor’s and patient’s assessment of the disease activity, and reduction in CRP levels.
CONCLUSIONS: There were no significant differences between the effects of treatment with leflunomide and methotrexate or sulfasalazine, but leflunomide monotherapy proved more effective than placebo in relieving symptoms and signs of RA.
Dominik Golicki; Maciej Newada; Joanna Lis; Kaja Pol; Tomasz Hermanowski; Małgorzata Tłustochowicz
Related Documents :
15750375 - The homeopathic preparation vertigoheel versus ginkgo biloba in the treatment of vertig...
22367105 - Functional outcomes and health-related quality of life in fracture victims 27 months af...
20642945 - Soft tissue profile response in extraction versus non-extraction orthodontic treatment.
16779975 - Centroid analysis of twin-block appliance treatment for class ii division 1 malocclusion.
20850795 - Neurocognitive deficits and personality traits among euthymic patients with mood disord...
11386015 - Benefits of the implementation of structured educational program in hypertension manage...
Publication Detail:
Type:  Journal Article     Date:  2012-01-11
Journal Detail:
Title:  Polskie Archiwum Medycyny Wewnętrznej     Volume:  122     ISSN:  1897-9483     ISO Abbreviation:  Pol. Arch. Med. Wewn.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401225     Medline TA:  Pol Arch Med Wewn     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  22-32     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Five-Year Follow-Up of 10 Patients Treated with Globus Pallidus Internus Deep Brain Stimulation for ...
Next Document:  A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?...